Devin Quinlan, Ph.D.
Investment and Operations Team
Devin Quinlan is a Principal on the investment team at MPM and BioImpact Capital, an affiliate manager of MPM, where he is focused primarily on early-stage investment and company creation.
Since joining the firm full-time in 2018, Devin has been involved in multiple investments, including Orna Therapeutics as well as stealth companies in gene editing, platform chemistry, and precision oncology. Additionally, Devin serves on the Board of Directors of Nextpoint Therapeutics and as a Board Observer at Crossbow Therapeutics, and he also supports MPM’s strategic relationships with Gilead Sciences, Ono Pharmaceutical, and Charles River Labs.
Prior to joining MPM and BioImpact Capital, Devin completed his Ph.D. in Biological Engineering at the Massachusetts Institute of Technology (MIT). His thesis was focused on uncovering structure-function relationships of antibodies which target viral antigens, including Ebola and Zika viruses. In addition to his academic research, Devin served as part of the inaugural leadership team of the MIT Biotech Group, which has since grown into the largest life-sciences student organization at MIT.
Devin is originally from Fresno, CA, and received his undergraduate degree in Bioengineering from the University of California, Los Angeles.